Lornoxicam, a new potent NSAID with an improved tolerability profile

Drugs of Today

Volumn 36, Issue 1, 2000, Pages 55-76

  Radhofer Welte, S ^a   Rabasseda, X ^b  

^a Pharma Consulting   (Austria)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ALUMINUM MAGNESIUM HYDROXIDE; CIMETIDINE; CLONAZEPAM; CLOTRIMAZOLE; DIAZEPAM; DIETHYLSTILBESTROL; LORNOXICAM; MEDAZEPAM; MELOXICAM; MICONAZOLE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; PIROXICAM; PRIMAQUINE; PROGESTERONE; SOLUGASTRIL; SULFAPHENAZOLE; TENOXICAM; TOLBUTAMIDE; VERAPAMIL; WARFARIN;

CLINICAL STUDY; DENTAL SURGERY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; INFLAMMATION; KIDNEY DISEASE; LIVER DYSFUNCTION; OSTEOARTHRITIS; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; POSTOPERATIVE PAIN; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0034003149     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.1.566627     Document Type: Review

References (62)

1. Berg, J., Christoph, T., Fellier, H. The analgesic NSAID lornoxicam inhibits COX-1/COX-2, iNOS and the formation of IL-6 in vitro. Naunyn-Schmied Arch Pharmacol 1998, 358 (Suppl. 2): R716.
2. Berg, J., Christoph, T., Widerna, M., Bodenteich, A. Isoenzyme-specific cyclooxygenase inhibitors: A whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line MonoMac6. J Pharmacol Toxicol Meth 1997, 37: 179-86.
3. Berg, J., Fellier, H., Christoph, T., Grarup, J., Stimmeder, D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res 1999, 48: 369-79.
4. Towart, R., Grarup, J., Stimmeder, D. Lornoxicam potentiates morphine antinociception during visceral nociception in the rat. Naunyn-Schmied Arch Pharmacol 1998, 358 (Suppl. 1): R172.
5. Hitzenberger, G., Radhofer-Welte, S., Takacs, F., Rosenow, D. Pharmacokinetics of lornoxicam in man. Postgrad Med J 1990, 66 (Suppl. 4): S22-6.
6. Radhofer-Welte, S., Dittrich, P. Determination of the novel non-steroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluid. J Chromatogr 1998, 707: 151-9.
7. Suwa T., Urano, H., Shinohara, Y., Kokatsu, J. Simultaneous high-performance liquid Chromatographic determination of lornoxicam and its 5'-hydroxy metabolite in human plasma using electrochemical detection. J Chromatogr 1993, 617: 105-10.
8. Welte, S., Ferber, H.P., Binder, D. A single dose pharmacokinetic and tolerability study of a new non steroidal anti-inflammatory drug CLTX. 3rd World Conf Clin Pharmacol Ther (Stockholm) 1986.
9. Bareggi, S.R., Gambaro, V., Valenti, M., Benvenuti, C. Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets. Arzneim-Forsch/Drug Res 1997, 47: 755-7.
10. Kukovetz, W.R., Dittrich, P. A randomized three-way cross-over, open label phase I bioequivalence study to compare the bioavailability of lornoxicam applied as suppository, as sachet and as oral film-coated tablet in 18 healthy volunteers. Clinical Trial Report CT 86, 1995. Data on file, Nycomed Pharma, Denmark.
11. Kukovetz, W.R., Wurzinger, A. Unicenter phase I study to investigate the bioavailability of lornoxicam applied as suppository and as i. v. administration in male healthy volunteers (n = 18). Clinical Trial Report CT 82, 1994. Data on file, Nycomed Pharma, Denmark.
12. Dittrich, P., Radhofer-Welte, S., Mayerhofer, S., Kukovetz, W.R., Ferber, H.P. Comparative pharmacokinetics of parenteral lornoxicam. Eur J Pharmarcol 1990, 183: 2265.
13. Mayerhofer, S., Welte, S., Magometschnigg, D., Ferber, H.P. The effect of food on pharmacokinetic parameters of the new NSAID lornoxicam in healthy volunteers. 3rd Intersci World Conf Inflamm (Monte Carlo) 1989, Abst 223.
14. Bree, F., Nguyen, P., Tillement, J.P. Blood binding of lornoxicam. Characterization of the HSA binding. Research Report No. 497, 1990. Data on file, Nycomed Austria GmbH.
15. Bree, F., Bechalany A., Nguyen, P., Testa, B., Tillement, J.P. HSA binding of 5 oxicams (NSAIDs) - Relationship with physicochemical parameters. In: Plasma Binding of Drugs and its Consequences. Belpaire, F., Bogaert, M., Tillement, J.P., Verbeeck, R. (Eds.). Academic Press 1991, 225.
16. Albengres, E., Uriens, S., Barre, J. et al. Clinical pharmacology of oxicams: New insights into the mechanisms of their dose-dependent toxicity. Int J Tissue React 1993, 15: 125-34.
17. Mayrhofer, F., Radhofer-Welte, S. Multiple dose study comparing lornoxicam in plasma and synovial fluid. Clinical Trial Report CT 21A, 1993. Data on file, Nycomed Pharma Denmark.
18. Pruss, T.P., Stroissnig, H., Radhofer-Welte, S. et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J 1990, 66 (Suppl. 4): S18-21.
19. Takacs, F., Welte, S., Ferber, H.P. Pharmacokinetic investigations with the new NSAID lornoxicam in rats. 3rd Intersci World Conf Inflamm (Monte Carlo) 1989, Abst 108.
20. Bonnabry, P., Leemann, T., Dayer, P. Hole of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 1996, 49: 305-8.
21. Kohl, C., Tracy, T.S., Radhofer-Welte, S. Identification of CYP2C9 as the major player in the metabolism of lornoxicam (Xefo®). Proc 6th Eur ISSX Meet (Gothenburg) 1997, 11: 162.
22. Luckow, V., Arnold, P.J. Identification of lornoxicam and its main metabolite in plasma of rabbit and man and in human urine by HPLC-UV-diode array and LC-thermospray-MS detections. Research Report No. 477, 1989. Data on file, Nycomed Austria GmbH.
23. Welz, W. Determination of HN-10004 in urine by gas chromatography/mass spectrometry. Research Report No. 774, 1993. Data on file, Nycomed Austria GmbH.
24. Waitzinger, J. Study on biliary excretion of lornoxicam in patients with T-drain. Clinical Trial Report CT 56, 1995. Data on file, Nycomed Pharma, Denmark.
25. Ravic, M., Johnston, A., Turner, P., Takacs, F., Rosenow, D.E. The effect of repeated oral doses of lornoxicam on antipyrine elimination in normal human volunteers. Hum Exp Toxicol 1991, 10: 375-7.
26. Ankier, S.I., Brimelow, A.E., Crome, P. et al. Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgrad Med J 1988, 64: 752-4.
27. Ravic, M., Salas-Herrera, I., Johnston, A., Turner, P., Foley, K., Rosenow D.E. A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam. Postgrad Med J 1993, 69: 865-6.
28. Ravic, M., Salas-Herrera, I., Johnston, A., Turner, P., Foley, K., Rosenow D.E. Influence of lornoxicam a new non-steroidal anti-inflammatory drug on lithium pharmacokinetics. Hum Psychopharmacol 1993, 8: 289-92.
29. Unseld, E., Radhofer-Welte, S., Molz, K.-H., Haug-Pihale, G., Grune, D., Frenzel, W. Disposition of lornoxicam and its 5'-hydroxy-metabolite in relation to the sparteine and mephenytoin oxidation polymorphism. Eur J Drug Metab 1993, 87-92.
30. Radhofer-Welte, S., Wurzinger, A. The potential for accumulation of lornoxicam. Internal Report, Feb. 17, 1995. Data on file, Nycomed Pharma, Denmark.
31. Verbeeck, R. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1990, 19: 44-66.
32. Brouwers, J.R.B.J., de Smet, P.A.G.M. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1994, 27: 462-85.
33. Kohl, C., Kocian, M., Paschinger, D., Radhofer-Welte, S. Interactions of potent tolbutamide 4-hydroxylase inhibitors with the metabolism of lornoxicam (Xefo®) in human liver microsomes. Proc 6th Eur ISSX Meet (Gothenburg) 1997, 11: 166.
34. Dittrich, P., Radhofer-Welte, S., Magometschnigg, D., Kukovetz, W.R., Mayerhofer, S., Ferber, H.P. The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID. Drugs Exp Clin Res 1990, 14: 57-62.
35. Ravic, M., Johnston, A., Turner, P., Ferber, H.P. A study of the interaction between lornoxicam and warfarin in healthy volunteers. Hum Exp Toxicol 1990, 9: 413-4.
36. Ravie, M., Salas, I.G., Turner, P. A clinical pharmacological study of chlortenoxicam and digoxin interaction. Eur J Clin Pharmacol 1989, 36 (Suppl.): A262.
37. Nahler, G., Windauer, U., Sprunt, E. An open study to determine the effect of renal insufficiency on the pharmacokinetics of lornoxicam and to assess the tolerability of the drug in volunteers with renal insufficiency. Clinical Study Report CT 74, 1993. Data on file, Nycomed Pharma, Denmark.
38. Haug-Pihale, G., Geisler, J. Study for evaluation of the pharmacokinetics after multiple dose administration of lornoxicam 8 mg tablets in patients with impaired liver function compared to healthy controls. Clinical Study Report CT 73, 1993. Data on file, Nycomed Pharma, Denmark.
39. Buritova, J., Besson, J.M. Potent anti-inflammatory/analgesic effects of lornoxicam in comparison to other NSAIDs: A c-Fos study in the rat. Inflammopharmacology 1997, 5: 331-41.
40. Buritova, J., Besson, J.M. Dose-related antiinflammatory/analgesic effects of lornoxicam: A spinal c-Fos protein study in the rat. Inflamm Res 1998, 47: 18-25.
41. Kullich, W., Klein, G. Influence of the nonsteroidal antiinflammatory drug lornoxicam i.v. on the secretion of the endogenous opiate peptides dynorphin and beta-endorphin. Akt Rheumatol 1992, 17: 128-32.
42. Cooper, S.A. Single-dose analgesic studies: The upside and downside of assay sensitivity. In: Advances in Pain Research and Therapy. Max, M., Portenoy, R., Laska, E. (Eds.). Raven Press: New York 1991.
43. Norholt, S.E. Treatment of acute pain following removal of mandibular third molars. Use of the dental pain model in pharmacological research and development of a comparable animal model. Int J Oral Maxillofac Surg 1998, 27 (Suppl. 1): 1-41.
44. Cooper, S.A., Fielding, A.F., Lucyk, D. et al. lornoxicam: Analgesic efficacy and safety of a new oxicam derivative. Adv Ther 1996, 13: 67-77.
45. Norholt, S.E., Sindet-Pedersen, S., Bugge, C. et al. A randomized, double-blind, placebo-controlled, dose-response study of the analgesic effect of lornoxicam after surgical removal of mandibular third molars. J Clin Pharmacol 1995, 35: 606-14.
46. Norholt, S.E., Sindet-Pedersen, S., Larsen, U. et al. Pain control after dental surgery: A double-blind, randomised trial of lornoxicam versus morphine. Pain 1996, 67: 335-43.
47. Patel, A., Skelly, A.M., Kohn, H., Preiskel, H.W. Double-blind placebo-controlled comparison of the analgesic effects of single doses of lornoxicam and aspirin in patients with postoperative dental pain. Br Dent J 1991, 170: 295-9.
48. Rainer, F., Klein, G., Mayerhofer, S. et al. A prospective, multicentre, open-label, uncontrolled phase II study of the local tolerability, safety and efficacy of intramuscular chlortenoxicam in patients with acute low back pain. Eur J Clin Res 1996, 8: 1-13.
49. Bernstein, R.M., Calin, H.J., Calin, A., Ollier, S. A comparison of the efficacy and tolerability of lornoxicam and indomethacin in ankylosing spondylitis. Eur J Rheumatol Inflamm 1992, 12: 6-13.
50. Kursten, F.W., Bias, P. Lornoxicam: An alternative in treatment of pain? A prospective study in patients suffering from chronic low back pain. Schmerz 1994, 8 (Suppl. 1): S51.
51. Mayerhofer, S., Siegmeth, W., Kolarz, G. et al. A multicentre, randomised, double-blind study comparing lornoxicam with conventional diclofenac in patients with chronic low back pain. Ann Exp Clin Med 1994, 5-6: 283-90.
52. Rosenow, D.E., Albrechtsen, M., Stolke, D. A comparison of patient-controlled analgesia with lornoxicam versus morphine in patients undergoing lumbar disk surgery. Anesth Analg 1998, 86: 1045-50.
53. Ilias, W., Jansen, M. Pain control after hysterectomy: An observer-blind, randomised trial of lornoxicam versus tramadol. Br J Clin Pract 1996, 50: 197-202.
54. Staunstrup, H., Ovesen, J., Kroner, K. A comparative study of IM lornoxicam and tramadol in the treatment of acute postoperative pain after knee surgery. 8th World Cong Pain 1996, Abst 176.
55. Staunstrup, H., Ovesen, J., Larsen, U.T. et al. Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain. J Clin Pharmacol 1999, 39: 834-41.
56. Berry, H., Bird, H.A., Black, C. et al. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis 1992, 51: 238-42.
57. Kidd, B., Frenzel, W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 1996, 23: 1605-11.
58. Bernstein, P.M., Frenzel, W. A comparative study of two dosage regimens of lornoxicam and a standard dosage of naproxen in patients with rheumatoid arthritis. Eur J Clin Res 1995, 7: 259-73.
59. Caruso, I., Montrone, F., Boari, L. et al. Lornoxicam versus diclofenac in rheumatoid arthritis: A double-blind multicenter study. Adv Ther 1994, 11: 132-8.
60. Aabakken, L., Osnes, M., Frenzel, W. Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers. Aliment Pharmacol Ther 1996, 10: 151-6.
61. Warrington, S.J., Dawnay, A., Johnston, A. et al. Chlortenoxicam and renal function of normal human volunteers. Hum Toxicol 1989, 8: 53-4.
62. Warrington, S.J., Lewis, Y., Dawnay, A. et al. Renal and gastrointestinal tolerability of lornoxicam, and effects on haemostasis and hepatic microsomal oxidation. Postgrad Med J 1990, 66 (Suppl. 4): S35-40.